| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1013672214 |
| P356 | DOI | 10.1007/BF03190985 |
| P698 | PubMed publication ID | 17479539 |
| P2093 | author name string | Jovan Popović | |
| P2860 | cites work | The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses | Q70283797 |
| Verapamil disposition kinetics in chronic atrial fibrillation | Q70791160 | ||
| Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships | Q71472633 | ||
| Pharmacokinetics of carbamazepine derived from a new tablet formulation | Q71946101 | ||
| Pharmacokinetic analysis of a new acenocoumarol tablet formulation during a bioequivalence study | Q71989340 | ||
| Pharmacokinetic parameters of verapamil and its active metabolite norverapamil in patients with hepatopathy | Q72141819 | ||
| Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans | Q73527408 | ||
| Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis | Q34448937 | ||
| Systemic availability of oral verapamil and effect on PR interval in man | Q34449063 | ||
| Influence of First-Pass Effect on Availability of Drugs on Oral Administration | Q34704483 | ||
| Calcium channel blocker class heterogeneity: select aspects of pharmacokinetics and pharmacodynamics | Q36109576 | ||
| Prediction of systemic availability from plasma-level data after oral drug administration | Q36504989 | ||
| Verapamil: a review of its pharmacological properties and therapeutic use. | Q39720756 | ||
| Calcium Antagonists Pharmacokinetic Properties | Q40146301 | ||
| Clinical Pharmacokinetics of Verapamil | Q40167931 | ||
| Estimation of biological availability after oral drug administration when the drug is eliminated by urinary excretion and metabolism | Q40322013 | ||
| Pharmacokinetic interaction between verapamil and everolimus in healthy subjects | Q42220164 | ||
| Classical Michaelis-Menten and system theory approach to modeling metabolite formation kinetics | Q42640316 | ||
| Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. 1984 | Q42759320 | ||
| Effect of metoprolol and verapamil administered separately and concurrently after single doses on liver blood flow and drug disposition | Q43502957 | ||
| Cubic spline functions and polynomials for calculation of absorption rate. | Q52215445 | ||
| Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil. | Q52435676 | ||
| Verapamil kinetics in normal subjects and patients with coronary artery spasm | Q52733119 | ||
| A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation | Q52798297 | ||
| Physiological disposition of verapamil in man | Q57072038 | ||
| Rapid high-pressure liquid chromatographic analysis of verapamil in blood and plasma | Q67003135 | ||
| Food, splanchnic blood flow, and bioavailability of drugs subject to first-pass metabolism | Q67340383 | ||
| P433 | issue | 1 | |
| P921 | main subject | verapamil | Q410291 |
| P304 | page(s) | 13-19 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | European Journal of Drug Metabolism and Pharmacokinetics | Q15757261 |
| P1476 | title | Validation of the hepatic blood flow rate model for verapamil first-pass metabolism | |
| P478 | volume | 32 |
| Q46459968 | Dual drug interactions via P-glycoprotein (P-gp)/ cytochrome P450 (CYP3A4) interplay: recent case study of oral atorvastatin and verapamil | cites work | P2860 |
Search more.